AVDL 241220 10.00P (AVDL241220P10000) Stock Options, News & Quotes

US OptionsDetailed Quotes

AVDL241220P10000

Watchlist

0.45
+0.30+200.00%

15min DelayClose Dec 3 16:00 ET

0.80High0.25Low

Intraday

5D
Daily

News

Avadel Chief Commercial Officer Resigns, Stock Down 14%
Seeking AlphaDec 3 10:45 ET
UBS Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Cuts Target Price to $22
Moomoo NewsNov 19 13:31 ET · Ratings
US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
GlobeNewswireNov 13 08:00 ET
H.C. Wainwright Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Cuts Target Price to $25
Moomoo NewsNov 13 06:31 ET · Ratings
Express News | Avadel Pharmaceuticals PLC : Piper Sandler Raises Target Price to $24 From $23
ReutersNov 12 23:56 ET

Comments

Stock_Drift

Oct 31 12:19

Unusual Volume Ticks. 1:18pm 🎃

$Roblox (RBLX.US)$ $Anavex Life Sciences (AVXL.US)$ $Santech Holdings (STEC.US)$ $Lead Real Estate (LRE.US)$ $Avadel Pharmaceuticals (AVDL.US)$ $Carvana (CVNA.US)$ $Lemonade (LMND.US)$ $Autonomix Medical (AMIX.US)$ $Peloton Interactive (PTON.US)$ $PLBY Group (PLBY.US)$ $Alphatec (ATEC.US)$ $Universal Security Instruments (UUU.US)$ $Biofrontera (BFRI.US)$ $Root Inc (ROOT.US)$
🎃⚡️🎃

Bigmoney Dreamer

Oct 31 12:16

$Avadel Pharmaceuticals (AVDL.US)$
Given its current financial standing and market movements, Avadel Pharmaceuticals is assessed as a moderately high-risk investment. The company's unprofitability, negative cash flow, and strong dependency on news-related catalysts pose potential risks. Nonetheless, the recently improved stock sentiment, coupled with analysts' positive forecasts, suggests some upside potential. The relatively high position in its volatility scale underscores the need for caution,...

Jaguar8

Oct 30 18:29

Hey 👋

$Avadel Pharmaceuticals (AVDL.US)$

Trytosaveabit

Oct 17 08:47

News

$Avadel Pharmaceuticals (AVDL.US)$ Reuters
4 mins ago
Avadel Pharmaceuticals Announces FDA Approval of Lumryz™ (Sodium Oxybate) Extended-Release Oral Suspension (Ciii) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older With Narcolepsy